Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Cogent Biosciences (COGT) to $14 from $17 and keeps a Buy rating on the ...

Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

Ancestry-based differences in frequencies of biomarkers that drive patient selection for treatment with precision oncology ...

Enliven Therapeutics' ELVN-001 shows promising results for CML patients. Click here to read what makes ELVN stock a ...

Elevations in biomarkers such as uterine artery pulsatility index and placental growth factor throughout pregnancy indicate ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) for the treatment of adults with locally advanced ...